Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-03-29 @ 6:07 AM
Study NCT ID:
NCT05369403
Status:
COMPLETED
Last Update Posted:
2025-03-19
First Post:
2022-05-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Sponsor:
Eli Lilly and Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
18499
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None